Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs

Rare Daily Staff

Chiesi Global Rare Diseases, the rare disease business division of Chiesi Group, has established a U.S. networkwide sponsorship of BioInnovation Labs, a developer and operator of life science coworking spaces with 12 active facilities in the United States and internationally.

Chiesi recently created a strategic innovation unit to scout and evaluate innovative therapeutic modalities emerging from academic, research institutes, and start-up and early-stage biotech organizations that may provide long-term solutions for patients with rare diseases.

“With our global rare diseases division headquartered in the research hub of Boston, we are in an ideal location to serve as a preferred partner for early-stage companies in this region and beyond, particularly to those that are investigating new modalities,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases.

The sponsorship of BioLabs will allow Chiesi to have access to BioLabs sites across the country. This gives Chiesi the opportunity to host office hours, workshops, and other onsite events for companies residing in their spaces, and to broadly engage with innovators in the life sciences sector. Chiesi will also be able to award two Golden Tickets per year, which are vouchers representing coworking lab and office use privileges for BioLabs locations that can be transferred to already residing startups or to startups that relocate to BioLabs sites.

“Our mission is to foster innovation and empower entrepreneurship by providing early-stage companies access to a powerful network of partners and mentors, and best-in-class lab space and essential lab services,” said Veena Krishnappa, senior director of Pharma Partnerships + Business Insights for BioLabs. “Our residents’ success relies on the support of global organizations like Chiesi, with their commitment to the principles of science and entrepreneurship, and their focus on nurturing a robust pipeline of groundbreaking scientific research.”

Photo: Giacomo Chiesi, head of Chiesi Global Rare Diseases